How to buy Cogent Biosciences stock | $13.01

Cogent Biosciences, Inc is a biotechnology business based in the US. Cogent Biosciences shares (UMRX) are listed on the NASDAQ and all prices are listed in US Dollars.

How to buy shares in Cogent Biosciences

1. Compare share trading platforms. If you're a beginner, look for a platform with low commissions, expert ratings and investment tools to track your portfolio. Narrow down top brands with our comparison table.
2. Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and bank information. Fund your account with a bank transfer, credit card or debit card.
3. Search for Cogent Biosciences. Find the stock by name or ticker symbol: UMRX. Research its history to confirm it's a solid investment against your financial goals.
4. Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until Cogent Biosciences reaches your desired price. To spread out your purchase, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
5. Decide on how many to buy. At last close price of USD$13.01, weigh your budget against a diversified portfolio that can minimize risk through the market's ups and downs. You may be able to buy a fractional share of Cogent Biosciences, depending on your broker.
6. Check in on your investment. Congratulations, you own a part of Cogent Biosciences. Optimize your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.

Cogent Biosciences share price

Use our graph to track the performance of UMRX stocks over time.

Cogent Biosciences shares at a glance

• Key figures

Information last updated 2020-12-01.

Latest market close	USD$13.01
52-week range	USD$0.295 - USD$11.78
50-day moving average	USD$6.1471
200-day moving average	USD$3.0183
Wall St. target price	USD$5
PE ratio	N/A
Dividend yield	N/A (0%)
Earnings per share (TTM)	USD$-1.358

Buy Cogent Biosciences shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.

Is it a good time to buy Cogent Biosciences stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Technical Analysis of Cogent Biosciences, Inc by TradingView

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Cogent Biosciences price performance over time

Historical closes compared with the close of $13.01 from 2020-12-04

1 week (2020-11-25)	36.37%
1 month (2020-11-06)	32.76%
3 months (2020-09-04)	491.36%
6 months (2020-06-05)	2,223.21%

1 year (2019-12-05)	1,839.76%
2 years (2018-12-04)	95.64%
3 years (2017-12-02)	N/A
5 years (2015-12-02)	N/A

Cogent Biosciences financials

Revenue TTM	USD$26.5 million
Gross profit TTM	USD$-21,210,000
Return on assets TTM	-25.76%
Return on equity TTM	0%
Profit margin	0%
Book value	$0.503
Market capitalisation	USD$73.2 million

TTM: trailing 12 months

Shorting Cogent Biosciences shares

There are currently 601,505 Cogent Biosciences shares held short by investors – that's known as Cogent Biosciences's "short interest". This figure is 39.1% down from 988,432 last month.

There are a few different ways that this level of interest in shorting Cogent Biosciences shares can be evaluated.

Cogent Biosciences's "short interest ratio" (SIR)

Cogent Biosciences's "short interest ratio" (SIR) is the quantity of Cogent Biosciences shares currently shorted divided by the average quantity of Cogent Biosciences shares traded daily (recently around 707652.94117647). Cogent Biosciences's SIR currently stands at 0.85. In other words for every 100,000 Cogent Biosciences shares traded daily on the market, roughly 850 shares are currently held short.

However Cogent Biosciences's short interest can also be evaluated against the total number of Cogent Biosciences shares, or, against the total number of tradable Cogent Biosciences shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Cogent Biosciences's short interest could be expressed as 0.01% of the outstanding shares (for every 100,000 Cogent Biosciences shares in existence, roughly 10 shares are currently held short) or 0.0211% of the tradable shares (for every 100,000 tradable Cogent Biosciences shares, roughly 21 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Cogent Biosciences.

Find out more about how you can short Cogent Biosciences stock.

Cogent Biosciences share dividends

We're not expecting Cogent Biosciences to pay a dividend over the next 12 months.

Cogent Biosciences share price volatility

Over the last 12 months, Cogent Biosciences's shares have ranged in value from as little as $0.295 up to $11.78. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Cogent Biosciences's is 1.3134. This would suggest that Cogent Biosciences's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).

Cogent Biosciences overview

Unum Therapeutics Inc., a biopharmaceutical company, focuses on developing a pipeline of novel therapies to treat cancer patients. The company's novel proprietary technology, known as Bolt-On Chimeric Receptor (BOXR), is designed to improve the functionality of engineered T cells by discovering and incorporating a ?bolt-on' transgene into a patients' engineered T cells to overcome resistance of the solid tumor microenvironment to T cell attack. Its advanced program, PLX9486, is a selective KIT D816V inhibitor that is being developed to treat patients with systemic mastocytosis and gastrointestinal stromal tumors. The company was founded in 2014 and is headquartered in Cambridge, Massachusetts.

Frequently asked questions

• What percentage of Cogent Biosciences is owned by insiders or institutions?

  Currently 35.403% of Cogent Biosciences shares are held by insiders and 31.044% by institutions.

• When does the fiscal year end for Cogent Biosciences?

  Cogent Biosciences's fiscal year ends in December.

• Where is Cogent Biosciences based?

  Cogent Biosciences's address is: 200 Cambridge Park Drive, Cambridge, MA, United States, 02140

• What is Cogent Biosciences's ISIN number?

  Cogent Biosciences's international securities identification number is: US19240Q2012

• What is Cogent Biosciences's CUSIP number?

  Cogent Biosciences's Committee on Uniform Securities Identification Procedures number is: 903214104